Medicare paves way for CAR-T in doctors' offices; liquid biopsy may be better way to decide who gets chemo

Medicare has taken a step toward making CAR-T more accessible, in anticipation of the procedure being used for increasingly common cancer types. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by       STAT+: Medicare paves the way for CAR-T in doctors offices By John Wilkerson Adobe Medicare officials have taken a step toward making a cutting-edge cancer treatment called CAR-T cell therapy available in doctor offices. Read More STAT+: Liquid biopsy study suggests a better way to decide which colorectal cancer patients need chemo By Jonathan Wosen Gillian Flaccus/AP The authors believe the findings show that liquid biopsies could one day help reshape the treatment of colorectal cancer. Read More STAT+: BioNTech CEO lays out vision for how mRNA and AI can power personalized medicine By Jonathan Wosen JASPER JACOBS/BELGA MAG/AFP via Getty Images With the acquisition of machine learning firm InstaDeep, BioNTech is betting that AI will play a key role in the future of mRNA medicines. Read More Sponsored Insight by Mirati A new treatment option is now available for the 2L KRASG12C-mutated NSCLC patient population Built for the challenge of KRASG12C, a new treatment option has been approved by the FDA for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic NSCLC as determined by an FDA approved test, and who have received at least one prior systemic therapy. Learn more about this new treatment option and its robust response to a relentless disease. Lawmakers again urge the Biden administration to use federal law to widen access to a cancer drug By Ed Silverman Kevin Dietsch/Getty Images Last month, the National Institutes of Health offered a vague timeline for addressing the march-in rights petition filed by cancer patients. Read More STAT+: Invitae's new CEO on why the genetic testing firm stopped chasing 'volume at all costs' By Jonathan Wosen Courtesy Invatae "The industry is learning that almost unlimited access to capital, chasing testing volume and adding cost on the back end, is not sustainable." Read More Tuesday, January 17, 2023       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2023, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser